Tilray Brands (NASDAQ:TLRY) Stock Price Up 6.7% Following Analyst Upgrade

Tilray Brands, Inc. (NASDAQ:TLRY)’s share price shot up 6.7% on Thursday after Roth Mkm upgraded the stock from a neutral rating to a buy rating. Roth Mkm now has a $10.00 price target on the stock. Tilray Brands traded as high as $6.66 and last traded at $6.55. 5,508,183 shares traded hands during mid-day trading, an increase of 49% from the average session volume of 3,697,357 shares. The stock had previously closed at $6.14.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Tilray Brands from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. TD Cowen decreased their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Monday. Canaccord Genuity Group began coverage on Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Finally, ATB Cormark Capital Markets raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tilray Brands presently has a consensus rating of “Hold” and a consensus target price of $11.20.

Key Stories Impacting Tilray Brands

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Record Q3 revenue beat and strong international cannabis growth — Tilray reported ~ $207M in Q3 revenue (+11% YoY) with international cannabis up ~73%, driving better-than-expected top-line results. GlobeNewswire press release
• Positive Sentiment: Brokerage support: Jefferies reiterated a Buy and kept a lofty $24 price target, citing improving fundamentals and medium-term visibility — this lifts the bull case on execution and upside if margins improve. Proactive Investors
• Positive Sentiment: Roth MKM upgraded TLRY to Buy with a $10 target — another bullish broker move adding conviction to the upside narrative. BayStreet.CA
• Neutral Sentiment: Company reaffirmed FY26 outlook and provided adjusted EBITDA guidance (FY26 $62–$72M) — guidance maintenance reduces near-term execution risk but still leaves questions on cash flow trajectory. Earnings call transcript
• Neutral Sentiment: Analyst divergence: ATB Cormark trimmed its target to $9 and set sector perform — shows mixed sell-side views (some bullish, some cautious). BayStreet.CA
• Negative Sentiment: EPS missed consensus: TLRY reported a $0.24 loss per share vs. an expected $0.14 loss, which pressured sentiment despite the revenue beat. MarketBeat earnings summary
• Negative Sentiment: Margin pressure and negative cash flow persist — analysts note rising competition and beverage segment weakness; adjusted profitability is improving but net margin remains negative. Seeking Alpha analysis
• Negative Sentiment: Some downgrades and lowered expectations (TD Cowen / other shops) hit consensus sentiment after the print, underlining execution and M&A risks that could cap the stock if momentum stalls. AmericanBankingNews

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in TLRY. Hilton Head Capital Partners LLC acquired a new position in shares of Tilray Brands in the 4th quarter valued at about $38,000. Schonfeld Strategic Advisors LLC boosted its position in shares of Tilray Brands by 4.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after purchasing an additional 6,182 shares in the last quarter. IFP Advisors Inc grew its stake in Tilray Brands by 14.3% during the fourth quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after purchasing an additional 7,541 shares during the period. Integrated Wealth Concepts LLC increased its holdings in Tilray Brands by 33.8% in the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock worth $64,000 after purchasing an additional 9,341 shares in the last quarter. Finally, CreativeOne Wealth LLC increased its holdings in Tilray Brands by 12.2% in the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after purchasing an additional 9,452 shares in the last quarter. 9.35% of the stock is owned by institutional investors.

Tilray Brands Stock Performance

The stock has a market capitalization of $763.12 million, a price-to-earnings ratio of -0.30 and a beta of 1.96. The company has a 50 day simple moving average of $7.37 and a 200-day simple moving average of $10.25. The company has a quick ratio of 1.72, a current ratio of 2.81 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last announced its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.10). The company had revenue of $206.73 million for the quarter, compared to analyst estimates of $201.35 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same period last year, the business earned ($0.87) EPS. As a group, equities research analysts expect that Tilray Brands, Inc. will post -0.2 EPS for the current fiscal year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.